mGluR4 negatively regulates the release of γ-aminobutyric acid (GABA) and glutamate in the indirect pathway of basal ganglia and is therefore considered to be a potential target for the treatment of motor symptoms in PD patients [90]. Here, GRM4 is linked to Parkinson disease.